These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 3910323)
1. Association between DR3 and thrombocytopenia due to gold or tiopronin. Case reports and review of the literature. Ferraccioli GF; Cavalieri F; Mercadanti M; Salaffi F; Ambanelli U; Savi M Clin Exp Rheumatol; 1985; 3(4):341-3. PubMed ID: 3910323 [TBL] [Abstract][Full Text] [Related]
3. Nephrotic syndrome induced by tiopronin: association with the HLA-DR3 antigen. Salvarani C; Macchioni P; Rossi F; Iori I; Filippi G Arthritis Rheum; 1985 May; 28(5):595-6. PubMed ID: 3873945 [No Abstract] [Full Text] [Related]
4. Serum IgA levels and ANA behaviour in rheumatoid patients with and without toxicity to remission-inducing drugs. Ferraccioli GF; Nervetti A; Mercadanti M; Cavalieri F Clin Exp Rheumatol; 1986; 4(3):217-20. PubMed ID: 2945684 [TBL] [Abstract][Full Text] [Related]
5. Toxicity due to remission inducing drugs in rheumatoid arthritis. Association with HLA-B35 and Cw4 antigens. Ferraccioli G; Peri F; Nervetti A; Ambanelli U; Savi M J Rheumatol; 1986 Feb; 13(1):65-8. PubMed ID: 3084782 [TBL] [Abstract][Full Text] [Related]
7. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. Bensen WG; Moore N; Tugwell P; D'Souza M; Singal DP J Rheumatol; 1984 Jun; 11(3):358-61. PubMed ID: 6234391 [TBL] [Abstract][Full Text] [Related]
8. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Coblyn JS; Weinblatt M; Holdsworth D; Glass D Ann Intern Med; 1981 Aug; 95(2):178-81. PubMed ID: 6942668 [TBL] [Abstract][Full Text] [Related]
9. Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold induced thrombocytopenia or proteinuria. Singal DP; Reid B; Green D; D'Souza M; Bensen WG; Buchanan WW Ann Rheum Dis; 1990 Aug; 49(8):582-6. PubMed ID: 2396862 [TBL] [Abstract][Full Text] [Related]
10. [Myasthenia caused by tiopronin during treatment of rheumatoid polyarthritis]. Menkes CJ; Job-Deslandre C; Bauer-Vinassac D; Rouillon A; Rousseau R Presse Med; 1988 Jun; 17(22):1156-7. PubMed ID: 2969543 [No Abstract] [Full Text] [Related]
11. Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. Wijnands MJ; Allebes WA; Boerbooms AM; van de Putte LB; van Riel PL Ann Rheum Dis; 1990 Oct; 49(10):798-800. PubMed ID: 1978639 [TBL] [Abstract][Full Text] [Related]
12. HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. Dahlqvist SR; Ström H; Bjelle A; Möller E Clin Rheumatol; 1985 Mar; 4(1):55-61. PubMed ID: 3157529 [TBL] [Abstract][Full Text] [Related]
13. HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. Speerstra F; Reekers P; van de Putte LB; Vandenbroucke JP Tissue Antigens; 1985 Jul; 26(1):35-40. PubMed ID: 3929421 [TBL] [Abstract][Full Text] [Related]
14. Tiopronin-nephropathy: clinical, pathological, immunological and immunogenetic characteristics. Ferraccioli GF; Peri F; Nervetti A; Mercadanti M; Cavalieri F; Dall'Aglio PP; Savi M; Ferrari C Clin Exp Rheumatol; 1986; 4(1):9-15. PubMed ID: 3516496 [TBL] [Abstract][Full Text] [Related]
15. Can gold therapy be used more safely in rheumatoid arthritis? Adverse drug reactions are more likely in patients with nodular disease, independent of HLA-DR3 status. Shah P; Griffith SM; Shadforth MF; Fisher J; Dawes PT; Poulton KV; Thomson W; Ollier WE; Mattey DL J Rheumatol; 2004 Oct; 31(10):1903-5. PubMed ID: 15468351 [TBL] [Abstract][Full Text] [Related]